API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/menarini-group-presented-initial-safety-and-efficacy-data-from-phase-1b2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-patients-with-er-her2--metastatic-breast-cancer-mbc-at-the-2023-san-antonio-breast--302011539.html
https://www.prnewswire.com/news-releases/menarini-group-announces-new-data-on-orserdu-elacestrant-at-the-2023-san-antonio-breast-cancer-symposium-and-on-elzonris-tagraxofusp-erzs-at-the-65th-american-society-of-hematology-annual-meeting-and-exposition-301994634.html
https://www.globenewswire.com//news-release/2023/10/18/2762408/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Samuraciclib-in-Combination-with-Elacestrant-in-Patients-with-Advanced-Breast-Cancer.html
https://www.ema.europa.eu/en/documents/overview/orserdu-epar-medicine-overview_en.pdf
https://www.businesswire.com/news/home/20230920907427/en/European-Commission-Approves-Menarini-Group%E2%80%99s-ORSERDU%C2%AE-Elacestrant-for-the-Treatment-of-Patients-with-ER-HER2--Locally-Advanced-or-Metastatic-Breast-Cancer-with-an-Activating-ESR1-Mutation
https://www.onclive.com/view/european-commission-approves-elacestrant-for-pretreated-esr1-er-her2-breast-cancer
https://www.pharmaceutical-technology.com/news/early-signals-suggest-oral-serds-potential-for-more-breast-cancer-patients/
https://www.prnewswire.com/news-releases/menarini-group-shares-new-analysis-from-emerald-clinical-study-of-orserdu-elacestrant-in-metastatic-breast-cancer-at-asco-2023-301835579.html
https://www.prnewswire.com/in/news-releases/menarini-group-shares-new-analysis-from-emerald-clinical-study-of-orserdu-elacestrant-in-metastatic-breast-cancer-at-asco-2023-301835579.html
https://www.fiercepharma.com/pharma/menarini-shows-big-pharmas-how-first-approval-oral-serd-breast-cancer
https://www.clinicaltrialsarena.com/news/carrick-therapeutics-menarini-breast-cancer/
https://www.clinicaltrialsarena.com/news/carrick-therapeutics-menarini-breast-cancer/
https://www.prnewswire.com/news-releases/menarini-groups-elacestrant-marketing-authorization-application-accepted-for-review-by-the-european-medicines-agency-ema-for-the-treatment-of-erher2--advanced-or-metastatic-breast-cancer-301609080.html
https://www.businesswire.com/news/home/20220811005185/en/Menarini-Group%E2%80%99s-Elacestrant-Granted-Priority-Review-by-the-U.S.-FDA-for-Patients-with-ERHER2--Advanced-or-Metastatic-Breast-Cancer
https://www.prnewswire.com/news-releases/menarini-group-and-radius-health-submit-new-drug-application-to-the-us-fda-for-elacestrant-301573553.html
https://www.prnewswire.com/news-releases/menarini-group-and-radius-health-inc-present-a-subgroup-analysis-from-the-elacestrant-pivotal-phase-3-emerald-clinical-trial-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting-301561886.html
https://www.fiercebiotech.com/biotech/menarini-chased-by-three-big-pharmas-records-win-breast-cancer-phase-3-plots-path-to-fda
https://finance.yahoo.com/news/menarini-group-radius-health-announce-123000913.html
https://www.prnewswire.com/news-releases/radius-health-amp-menarini-gruppe-liefern-elacestrant-update-868357385.html
https://www.prnewswire.com/news-releases/radius-health--menarini-group-provide-elacestrant-update-301138118.html
https://www.prnewswire.com/news-releases/radius-health--menarini-group-provide-elacestrant-update-301138118.html